Podcasts about rfs

In this reflective, funny episode, Lewis and Gemma reunite in the same room, fresh from a Royal Forestry Society award and a whirlwind visit to Westonbirt Arboretum. Using the provocatively titled book *We Need Your Art: Stop ***ing Around and Make Something as a springboard, they unpack how Western culture sidelines creativity, why Forest School's process-first ethos matters, and how to plan for failure with kinder self-talk. Expect talk of “shitty art” challenges, class and permission to fail, celebrating small milestones without slipping into praise economies, acorn milk experiments, squirrel mysteries, and the radical power of modelling silliness so children feel safe to try, tinker, and try again.TENTSILE — Tree tents that transform tricky ground into magical campouts. Listeners get 10% off with code ForestChildren10 at checkout.Chris Holland — Nature connection resources we genuinely rate. Explore his 54-page plant guide and more via our affiliate link: https://chrisholland.myshopify.com/?ref=ForestSchoolPodcast00:43 – Back together: RFS award, Westonbirt Arboretum, and “Square Oil” giggles04:24 – The book: bold Sharpie manifestos that kick you into making06:15 – Structure: reflective prompts, a two-week “make something daily” challenge, and looking back07:36 – Why Forest School is a curriculum-free haven for creativity, not metrics08:52 – How school and society infantilise art and push it to the margins11:44 – Product versus process: performances, gifts, and the “motivation soup”19:18 – Class, safety nets, and permission to fail in creative careers21:39 – Plan your self-talk for when you fail; modelling kinder language with parents33:26 – Celebrating small milestones together without turning joy into judgment52:32 – Stop at 80%: making endings easy, sustainable, and actually enjoyable

Policy is slamming the countryside. Chris Clayton (DTN/Progressive Farmer) explains how tariffs, China's pivot to Brazilian soybeans, and a USDA shutdown are colliding with harvest to pressure basis, storage, and cash flow—and to derail rural land sales. We dig into why China (historically 25–33% of U.S. soybean demand) is buying from Brazil (COFCO/ports, crush), how that drives basis widening and elevator capacity issues, and what could actually move the needle: biofuels (biodiesel/renewable diesel, ethanol, SAF). We also lay out shutdown fallout—FSA farm ownership/operating loans stalled, CRP payments paused, NRCS (EQIP/CSP) frozen—plus the limited upside from CCC/ECAP‑style aid. If you buy/sell rural land or advise landowners, this is the unvarnished read on farmland values, buyer pools, and the next 3–6 months. Why It Matters Deals slip/die: FSA loans are stopped, shrinking the buyer pool just as post‑harvest listings hit. Cash crunch: Basis widening + storage pressure at harvest reduce liquidity for down payments and improvements. Programs on ice: CRP checks delayed; NRCS projects paused—affecting valuations and conservation‑driven marketing. Demand hinges on policy: RFS, biodiesel/renewable diesel, and SAF tax credits will decide soy oil crush, corn demand, and rents. Strategy reality: Diversified ops with cattle are weathering this better than row‑crop‑only farms. Progressive Farmer https://www.dtnpf.com/agriculture/web/ag/home   National Land Realty https://www.nationalland.com  

The battle for year round E15 is not new, but in the last several weeks, it has become increasingly urgent. Though lawmakers have expressed support again and again for expanded rules that would create additional demand for ethanol around the country, farmers and their advocates continue to wait for changes, and now with a gigantic corn crop about to flood the market, and hamstring prices, any bit of extra demand could provide relief.To help us understand where the E15 story currently stands, DTN Environmental Editor Todd Neeley joins us today with analysis of the latest announcements. The conversation continues with updates on the Small Refinery Exemption issue — a longer range issue that's been lingering at the EPA and in the courts since the first Trump administration. Then we'll get updates on the latest RFS volume announcements and what's happening on the trade front as the U.S. disputes Brazilian biofuel tariff levels. We'll also talk through the latest news on the 45Z tax credit, a recent plant acquisition, and what might be ahead as more federal uncertainty — and a potential government shutdown — loom. 

Šoreiz raidījumā Piespēle runājam tikai par sporta karalieni vieglatlētiku. Māris un Mārtiņš devās uz Rīgas lidostu sagaidīt mājās pasaules vicečempioni šķēpa mešanā Aneti Sietiņu, bet Gunārs Jākobsons ciemos sagaidījas pasaules čempionāta dalībnieku Raivo Saulgriezi un viņa tēvu. Nedēļas topā: Latvijas futbola virslīgā aizvadīts Rīgas derbijs, kurā “Riga” un RFS cīnījās bezvārtu neizšķirti - tas vēl vairāk pietuvo “Riga” komandu čempiontitulam, savukārt “Grobiņa” pēc zaudējuma “Liepājai” atlaiž ilggadējo galveno treneri Viktoru Dobrecovu; Nacionālajā hokeja līgā sākušās pirmssezonas pārbaudes spēles, labi sevi apliecina Rodrigo Ābols un Zemgus Girgensons, Pitsburgas “Penguins” vārtos pie iespējas ticis arī Artūrs Šilovs. Floridas “Panthers” kapteinim Aleksandram Barkovam krustenisko saišu plīsums un sezona, ļoti iespējams, beigusies vēl nesākusies; Latvijas Sporta federāciju padome aicina nākamajos divos gados palielināt gan azartspēļu, gan izložu nodokli, lai sporta budžetā papildus ieripotu vairāk nekā septiņi miljoni eiro.

「米環境保護庁、再生可能燃料基準の補足規則案を発表　小規模製油所免除への対応示す」　米環境保護庁（EPA）は9月16日、再生可能燃料基準（RFS）プログラムにおける2026年および2027年の再生可能燃料量要件（RVO）に関する補足規則案（SNPRM）を発表した。The post 米環境保護庁、再生可能燃料基準の補足規則案を発表　小規模製油所免除への対応示す first appeared on サステナビリティ・ESG金融・投資メディア - HEDGE GUIDE.

Šoreiz iknedēļas informatīvi izklaidējošajā raidījumā Andris ar Valdi būs šokā, kā Eurobasket 2025 ir beidzies. Raidījuma tēmas: - ️Eurobasket fināls; - Eurobasket All Stars; - ️Atamans ir labākais treneris Eiropā?; - Kanelo pret Kroufordu; - ️Luka pērk māju LA; - Latvija dāvā pilsonības; - Meivezers liek likmi; - RFS zaudē; - Nikoloto kritizē futbola sabiedrību; - Sākas PČ vieglatlētikā;

study link :https://pmc.ncbi.nlm.nih.gov/articles/PMC9884822/pdf/fspor-04-1048655.pdfKey takeaways: Gait modifications can immediately reduce patellofemoral pain in some runners.The most effective strategies were increasing step rate by 10% and adopting a forefoot strike pattern.Runners with a rearfoot strike benefitted more from forefoot strike and “running softer,” while non-RFS mainly improved with a higher step rate.Reductions in patellofemoral joint force were linked to pain decreases, but not always — suggesting other mechanisms (psychological/central factors) may also contribute.Increasing step rate is likely the safest first option; forefoot strike may work but carries higher Achilles tendon load, so requires caution.

Rory speaks with Bloomberg expert Brett Gibbs about the Renewable Fuel Standard (RFS) and its profound impact across energy, agriculture, and gasoline prices. Brett highlights the market's policy-driven nature, contrasting stable ethanol volumes with the rapid, four-fold growth of renewable diesel, which now significantly displaces petroleum diesel. A key distinction is renewable diesel's chemical identity to petroleum diesel, allowing one-for-one substitution and no blend limits, unlike biodiesel. However, renewable diesel production remains uneconomic without crucial policy support like RFS RINs and tax credits, as feedstock costs (e.g., soybean oil at $4/gallon) vastly exceed petroleum diesel prices ($2.33/gallon). The conversation delves into the RFS's complex credit system and recent policy shifts favoring domestic feedstocks, such as the removal of indirect land use change penalties on US soybean oil, boosting its tax credit value. While roughly 50% of feedstocks are waste-based, scaling these is challenging, leading to reliance on virgin oils like soybean oil, which accounts for up to 50% of US soybean oil production now. Looking ahead, the US biofuel industry is expected to see a plateau in growth, with the administration aiming for stable 80% utilization to balance agricultural support with consumer fuel costs, while buying time for new technologies. Key indicators for tracking the market include the D4 RIN price and soybean oil prices

Raidījumā Piespēle, protams, runājam par basketbolu. Rīgā sācies Eiropas basketbola čempionāta finālturnīrs vīriešu izlasēm. Sarunā ar Latvijas basketbola izlases kandidātu šajā vasarā Mārtiņu Laksu izzinām to, ko spēlētāji upurē, lai sasniegtu sapni spēlēt valstsvienībā. Laksa šajā vasarā vienā no izlases treniņiem savainoja plecu, laukumā viņš varētu atgriezties vien decembrī. Mārtiņam nav līguma jaunajai sezonai, tāpēc cīņa par vietu Latvijas izlasē viņam šovasar bija milzu risks. Rubrikā “Ciemos pie Gunāra Jākobsona” šoreiz bijusī Latvijas Radio sporta žurnāliste un arī basketbola trenere Inita Kresa-Katkovska un jaunatnes basketbola treneris Mārtiņš Fomins. Nedēļas topā: Latvijas vīriešu basketbola izlase Eiropas čempionātu Rīgā sāk ar uzvaru un diviem zaudējumiem, bet svarīgākie mači vēl tikai gaidāmi; Šoruden bez Eirokausu līgas fāzes - gan “Riga”, gan RFS futbolisti tomēr nesasniedz Konferences līgas pamatturnīru; ASV atklātā tenisa čempionāta vienspēļu pamatsacensībās pirmoreiz trīs Latvijas tenisistes, bet visām turnīrs ļoti ātri arī beidzas.

In this episode, Leslie Bellas, Vice President, Regulatory Affairs, American Fuel and Petrochemical Manufacturers (AFPM), discusses the U.S. EPA's recent RFS proposal, including costs, feedstock challenges and a simple change to cut regulatory costs, among other items.

Šoreiz raidījumā pievērsīsimies profesionālu sportistu sevis meklējumiem pēc karjeras noslēguma. Nereti tas ir ļoti grūts un sarežģīts process, labo pieredzes stāstu līdz šim publiski izskanējis maz.  Raidījumā Piespēle saruna ar bijušo brīvā stila cīkstoni, četrkārtējo Eiropas čempioni Anastasiju Grigorjevu. Lai gan viņai jau bija vairākas augstākās izglītības, bez pamatīgas personīgās krīzes pēc karjeras noslēguma viņa tomēr neizvairījās. Nedēļas topā: -Latvijas vīriešu basketbola izlasei divas pārbaudes spēles savā laukumā - zaudējums Lietuvai papildlaikā ar 105:109, bet ar 100:88 uzvarēta Slovēnija; -Latvijas 16 gadīgo puišu basketbola izlase Eiropas čempionātu noslēdz sestajā pozīcijā; -Latvijas vīriešu volejbola izlasei ne tā pārliecinošākā spēle laukumā, bet nodrošināta biļete uz Eiropas čempionātu, finālturnīram kvalificējusies arī sieviešu volejbola izlase; -Abi galvaspilsētas futbola klubi RFS un “Riga” spēlēs UEFA Konferences līgas kvalifikācijas izšķirošajā kārtā; -Ernests Gulbis piektdienas vakarā pēkšņi atkāpjas no Latvijas Tenisa savienības prezidenta amata, atlūgumu iesniedz arī ģenerālsekretārs Jānis Mellups.

Šoreiz raidījumā Piespēle izzinām, kas ir Latvijas atklātā hokeja čempionāta jeb Baltijas līgas jaunpienācēja Kijivas “Capitals” vienība. Par to detalizēti stāsta šīs komandas pārstāvis Jēkabs Rēdlihs. Nedēļas topā: Latvijas vīriešu basketbola izlase aizvadījusi gandrīz nedēļu ilgu treniņnometni Slovēnijā, bet pirmajā pārbaudes spēlē ar 75:91 zaudē Itālijai; Vīriešu volejbola izlasei mainīgas sekmes pārbaudes spēlēs Igaunijā - uzvara un zaudējums. Šovakar sieviešu izlasei izšķirošā Eiropas čempionāta kvalifikācijas spēle viesos Melnkalnē; RFS futbolistiem klupiens UEFA Eiropas līgas kvalifikācijas trešās kārtas kārtas ievadā pret somu “KuPS”, “Riga” pārliecinoši tiek galā ar Jeruzalemes “Beitar”; Latvijas jaunajiem vieglatlētiem mainīgas sekmes Eiropas čempionātā 20 gadniekiem, sudraba medaļa arī 3000 metru skrējējam Kristeram Kudlim; Par Latvijas Handbola federācijas ģenerālsekretāru kļūst bijušais sporta žurnālists Uldis Strautmanis, vīriešu izlasē uzreiz veic galvenā trenera nomaiņu.

Renewable Fuels Association President and CEO Geoff Cooper talks about the 20th anniversary of the Renewable Fuel Standard (RFS), which was part of the Energy Policy Act of 2005 signed by President George W. Bush on August 8 of that year at Sandia National Laboratory in Albuquerque, New Mexico. Read RFA's report on the RFS at Twenty.

Raidījumā Piespēle iepazīstam Kanādas nacionālo vasaras sporta veidu lakrosu. Tā ir viena no senākajām komandu sporta spēlēm pasaulē, radusies 12. gadsimtā. Pirmie to sāka spēlēt Ziemeļamerikas pamatiedzīvotāji. Latvijā šo sporta veidu šī gadsimta ievadā aizsāka Aigars Grīnbergs, bet pavisam nesen Latvijas vīriešu izlase Eiropas čempionātā izcīnīja augsto piekto vietu. Studijā viesojas Latvijas Lakrosa federācijas prezidents Nikolajs Karlsons, kurš stāsta plašāk par šī sporta veida attīstību pašu mājās. Nedēļas topā: Latvijas U-18 un jaunāku puišu basketbola izlase pārsteidz daudzus un Eiropas čempionātā aizkļūst līdz mačam par bronzas medaļām; Latvijas vīriešu basketbola izlase 17 vīru sastāvā dodas uz treniņnometni Slovēnijā, 9.augustā Triestē pirmā pārbaudes spēle; RFS futbolisti izstājas Čempionu līgas kvalifikācijas otrajā kārtā, “Riga” izglābjas Gruzijā un soļo tālāk Konferences līgā; Eiropas čempionātā pludmales volejbolā šoreiz latviešu pāriem dalīta piektā, devītā un 25.vieta; Eiropas čempionāta kvalifikācijā volejbolā sieviešu izlase piecos setos zaudē Bosnijai un Hercegovinai, bet sper soli tuvāk finālturnīram.

Atlicis tikai mēnesis līdz Eiropas čempionāta finālturnīra sākumam. Latvijas vīriešu basketbola izlase jau 27. augustā aizvadīs savu pirmo spēli pret Turciju. Tāpēc arī viss raidījums Piespēle veltīts Eiropas čempionātam basketbolā.  Ieklausāmies Eiropas basketbola čempionāta reklāmas rullīša filmēšanas aizkulisēs. Latvijas Radio tiešraidē pārraidīs visas Latvijas valstsvienības spēles, tās komentēs Andrejs Siliņš un Mārtiņš Kļavenieks, bet ekspertu studijā būs Māris Bergs un Uvis Helmanis. Rubrikā "Ciemos pie Gunāra Jākobsona" arī saruna par basketbolu. No 14. līdz 17. augustam Rīgā risināsies 1939. gada Eiropas vicečempiona Alfrēda Kraukļa tradicionālais piemiņas turnīrs basketbolā. Stāsta turnīra rīkotāji Jānis Labuts un Kristīne Karašniece-Bullīte. Nedēļas topā: RFS futbolistiem pamatīgs zaudējums  pret Malmes klubu Čempionu līgas kvalifikācijas otrās kārtas ievadā, “Riga” nosargā uzvaru Konferences līgas kvalifikācijas mačā; Latvijas izlases basketbolisti paraksta jaunus līgumus augsta līmeņa čempionātos - Kristers Zoriks pārceļas uz Spāniju, Mārcis Šteinbergs paliek Manrēsā, Kārlis Šiliņš - uz Turciju; Latvijas jaunie sportisti ar labiem rezultātiem startē Eiropas jaunatnes olimpiskajā festivālā Ziemeļmaķedonijā; Latvijas 20 gadīgo puišu izlases basketbolisti pēc sešu gadu pauzes atgriežas Eiropas elitē.

I veckans avsnitt snackar vi ner matcherna mot RFS och Öster, synar prestationerna, hyllar och ifrågasätter och pratar nyförvärv, byten och vad som egentligen händer med MFF:s spel just nu. Dessutom: VD Niclas Carlnén tackar för sig efter elva år, vad betyder det för klubbens framtid?Patreon blir du enklast här - Patreon.com/HDN

Šoreiz raidījumā Piespēle runājam par šahu un vienu no visu laiku izcilākajiem tā spēlētājiem - rīdzinieku Mihailu Tālu. Tāla zvaigzne pie pasaules šaha debesjuma uzmirdzēja 1960. gadā, kad viņš kļuva par pasaules čempionu. Diemžēl tronī izdevās noturēties vien gadu, pēc tam šo panākumu vairs atkārtot viņš nespēja. Kas īsti bija un joprojām ir Tāla fenomens, un kāds cilvēcīgi bija šahists ikdienā - par to saruna ar nule kā klajā nākušās grāmatas “Eksčempions. Mihails Tāls” autoru, šaha treneri un vēsturnieku Andri Tihomirovu. Nedēļas topā: RFS futbolisti soļo tālāk Čempionu līgas kvalifikācijā, “Audai” un “Daugavpilij” izstāšanās Konferences līgas pirmajā kārtā; “Latvijas Universitāte” arī nākamajā sezonā tomēr spēlēs apvienotajā basketbola līgā - turnīrā 14 komandas, Rīgas “Zeļļi” tomēr atsakās no vietas FIBA Eiropas kausa kvalifikācijā; Aļonai Ostapenko turpina neveikties visaugstākās raudzes tenisa turnīru finālos - zaudējums Vimbldonas dubultspēlēs un neizmantota iespēja kļūt par dubultspēļu ranga līderi.

Iowa Business Report Wednesday EditionJul. 16, 2025  Iowa Secretary of Agriculture and Land Stewardship Mike Naig on why the new federal RFS numbers are good news for Iowa's economy. 

Headlines on today's episode include:-USDA unveils farm security action plan-Chairman Thompson discusses National Farm Security Action Plan-Biofuel groups testify at EPA hearing on 2026-27 Renewable Fuel Standards-Petroleum groups push back on EPA's RFS proposal-Farmers say let's get the deals doneSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Diwakar Davar and Dr. Jason Luke discuss novel agents in melanoma and other promising new data in the field of immunotherapy that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Diwakar Davar: Hello. My name is Diwakar Davar, and I am welcoming you to the ASCO Daily News Podcast. I'm an associate professor of medicine and the clinical director of the Melanoma and Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. Today, I'm joined by my colleague and good friend, Dr. Jason Luke. Dr. Luke is a professor of medicine. He is also the associate director of clinical research and the director of the Phase 1 IDDC Program at the University of Pittsburgh's Hillman Cancer Center. He and I are going to be discussing some key advancements in melanoma and skin cancers that were presented at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Jason, it is great to have you back on the podcast. Dr. Jason Luke: Thanks again so much for the opportunity, and I'm really looking forward to it. Dr. Diwakar Davar: Perfect. So we will go ahead and start talking a little bit about a couple of key abstracts in both the drug development immunotherapy space and the melanoma space. The first couple of abstracts, the first two, will cover melanoma. So, the first is LBA9500, which was essentially the primary results of RELATIVITY-098. RELATIVITY-098 was a phase 3 trial that compared nivolumab plus relatlimab in a fixed-dose combination against nivolumab alone for the adjuvant treatment of resected high-risk disease. Jason, do you want to maybe give us a brief context of what this is? Dr. Jason Luke: Yeah, it's great, thanks. So as almost all listeners, of course, will be aware, the use of anti–PD-1 immunotherapies really revolutionized melanoma oncology over the last 10 to 15 years. And it has become a standard of care in the adjuvant setting as well. But to review, in patients with stage III melanoma, treatment can be targeted towards BRAF with BRAF and MEK combination therapy, where that's relevant, or anti–PD-1 with nivolumab or pembrolizumab are a standard of care. And more recently, we've had the development of neoadjuvant approaches for palpable stage III disease. And in that space, if patients present, based on two different studies, either pembrolizumab or nivolumab plus ipilimumab can be given prior to surgery for somewhere in the 6- to 9-week range. And so all of these therapies have improved time-to-event endpoints, such as relapse-free or event-free survival. It's worth noting, however, that despite those advances, we've had a couple different trials now that have actually failed in this adjuvant setting, most high profile being the CheckMate-915 study, which looked at nivolumab plus ipilimumab and unfortunately was a negative study. So, with RELATIVITY-047, which was the trial of nivolumab plus relatlimab that showed an improvement in progression-free survival for metastatic disease, there's a lot of interest, and we've been awaiting these data for a long time for RELATIVITY-098, which, of course, is this adjuvant trial of LAG-3 blockade with relatlimab plus nivolumab. Dr. Diwakar Davar: Great. So with that, let's briefly discuss the trial design and the results. So this was a randomized, phase 3, blinded study, so double-blinded, so neither the investigators knew what the patients were getting, nor did the patients know what they were getting. The treatment investigational arm was nivolumab plus relatlimab in the fixed-dose combination. So that's the nivolumab standard fixed dose with relatlimab that was FDA approved in RELATIVITY-047. And the control arm was nivolumab by itself. The duration of treatment was 1 year. The patient population consisted of resected high-risk stage III or IV patients. The primary endpoint was investigator-assessed RFS. Stage and geography were the standard stratifying factors, and they were included, and most of the criteria were balanced across both arms. What we know at this point is that the 2-year RFS rate was 64% and 62% in the nivolumab and nivolumab-combination arms, respectively. The 2-year DMFS rate was similarly equivalent: 76% with nivolumab monotherapy, 73% with the combination. And similar to what you had talked about with CheckMate 915, unfortunately, the addition of LAG-3 did not appear to improve the RFS or DMFS compared to control in this patient population. So, tell us a little bit about your take on this and what do you think might be the reasons why this trial was negative? Dr. Jason Luke: It's really unfortunate that we have this negative phase 3 trial. There had been a lot of hope that the combination of nivolumab with relatlimab would be a better tolerated combination that increased the efficacy. So in the metastatic setting, we do have 047, the study that demonstrated nivolumab plus relatlimab, but now we have this negative trial in the adjuvant setting. And so as to why exactly, I think is a complicated scenario. You know, when we look at the hazard ratios for relapse-free survival, the primary endpoint, as well as the secondary endpoints for distant metastasis-free survival, we see that the hazard ratio is approximately 1. So there's basically no difference. And that really suggests that relatlimab in this setting had no impact whatsoever on therapeutic outcomes in terms of efficacy. Now, it's worth noting that there was a biomarker subanalysis that was presented in conjunction with these data that looked at some immunophenotyping, both from circulating T cells, CD8 T cells, as well as from the tumor microenvironment from patients who were treated, both in the previous metastatic trial, the RELATIVITY-047 study, and now in this adjuvant study in the RELATIVITY-098 study. And to briefly summarize those, what was identified was that T cells in advanced melanoma seemed to have higher expression levels of LAG-3 relative to T cells that are circulating in patients that are in the adjuvant setting. In addition to that, there was a suggestion that the magnitude of increase is greater in the advanced setting versus adjuvant. And the overall summary of this is that the suggested rationale for why this was a negative trial may have been that the target of LAG-3 is not expressed as highly in the adjuvant setting as it is in the metastatic setting. And so while the data that were presented, I think, support this kind of an idea, I am a little bit cautious that this is actually the reason for why the trial was negative, however. I would say we're not really sure yet as to why the trial was negative, but the fact that the hazard ratios for the major endpoints were essentially 1 suggests that there was no impact whatsoever from relatlimab. And this really makes one wonder whether or not building on anti–PD-1 in the adjuvant setting is feasible because anti–PD-1 works so well. You would think that even if the levels of LAG-3 expression were slightly different, you would have seen a trend in one direction or another by adding a second drug, relatlimab, in this scenario. So overall, I think it's an unfortunate circumstance that the trial is negative. Clearly there's going to be no role for relatlimab in the adjuvant setting. I think this really makes one wonder about the utility of LAG-3 blockade and how powerful it really can be. I think it's probably worth pointing out there's another adjuvant trial ongoing now of a different PD-1 and LAG-3 combination, and that's cemiplimab plus fianlimab, a LAG-3 antibody that's being dosed from another trial sponsor at a much higher dose, and perhaps that may make some level of difference. But certainly, these are unfortunate results that will not advance the field beyond where we were at already. Dr. Diwakar Davar: And to your point about third-generation checkpoint factors that were negative, I guess it's probably worth noting that a trial that you were involved with, KeyVibe-010, that evaluated the PD-1 TIGIT co-formulation of vibostolimab, MK-4280A, was also, unfortunately, similarly negative. So, to your point, it's not clear that all these third-generation receptors are necessarily going to have the same impact in the adjuvant setting, even if they, you know, for example, like TIGIT, and they sometimes may not even have an effect at all in the advanced cancer setting. So, we'll see what the HARMONY phase 3 trial, that's the Regeneron cemiplimab/fianlimab versus pembrolizumab control with cemiplimab with fianlimab at two different doses, we'll see how that reads out. But certainly, as you've said, LAG-3 does not, unfortunately, appear to have an impact in the adjuvant setting. So let's move on to LBA9501. This is the primary analysis of EORTC-2139-MG or the Columbus-AD trial. This was a randomized trial of encorafenib and binimetinib, which we will abbreviate as enco-bini going forward, compared to placebo in high-risk stage II setting in melanoma in patients with BRAF V600E or K mutant disease. So Jason, you know, you happen to know one or two things about the resected stage II setting, so maybe contextualize the stage II setting for us based on the trials that you've led, KEYNOTE-716, as well as CheckMate-76K, set us up to talk about Columbus-AD. Dr. Jason Luke: Thanks for that introduction, and certainly stage II disease has been something I've worked a lot on. The rationale for that has been that building off of the activity of anti–PD-1 in metastatic melanoma and then seeing the activity in stage III, like we just talked about, it was a curious circumstance that dating back about 7 to 8 years ago, there was no availability to use anti–PD-1 for high-risk stage II patients, even though the risk of recurrence and death from melanoma in the context of stage IIB and IIC melanoma is in fact similar or actually higher than in stage IIIA or IIIB, where anti–PD-1 was approved. And in that context, a couple of different trials that you alluded to, the Keynote-716 study that I led, as well as the CheckMate 76K trial, evaluated pembrolizumab and nivolumab, respectively, showing an improvement in relapse-free and distant metastasis-free survival, and both of those agents have subsequently been approved for use in the adjuvant setting by the US FDA as well as the European Medicines Agency.  So bringing then to this abstract, throughout melanoma oncology, we've seen that the impact of anti–PD-1 immunotherapy versus BRAF and MEK-targeted therapy have had very similar outcomes on a sort of comparison basis, both in frontline metastatic and then in adjuvant setting. So it was a totally reasonable question to ask: Could we use adjuvant BRAF and MEK inhibitor therapy? And I think all of us expected the answer would be yes. As we get into the discussion of the trial, I think the unfortunate circumstance was that the timing of this clinical trial being delayed somewhat, unfortunately, made it very difficult to accrue the trial, and so we're going to have to try to read through the tea leaves sort of, based on only a partially complete data set. Dr. Diwakar Davar: So, in terms of the results, they wanted to enroll 815 patients, they only enrolled 110. The RFS and DMFS were marginally improved in the treatment arm but certainly not significantly, which is not surprising because the trial had only accrued 16% to 18% of its complete accrual. As such, we really can't abstract from the stage III COMBI-AD data to stage II patients. And certainly in this setting, one would argue that the primary treatment options certainly remain either anti–PD-1 monotherapy, either with pembrolizumab or nivolumab, based on 716 or 76K, or potentially active surveillance for the patients who are not inclined to get treated.  Can you tell us a little bit about how you foresee drug development going forward in this space because, you know, for example, with HARMONY, certainly IIC disease is a part of HARMONY. We will know at least a little bit about that in this space. So what do you think about the stage IIB/C patient population? Is this a patient population in which future combinations are going to be helpful, and how would you think about where we can go forward from here? Dr. Jason Luke: It is an unfortunate circumstance that this trial could not be accrued at the pace that was necessary. I think all of us believe that the results would have been positive if they'd been able to accrue the trial. In the preliminary data set that they did disclose of that 110 patients, you know, it's clear there is a difference at a, you know, a landmark at a year. They showed a 16% difference, and that would be in line with what has been seen in stage III. And so, you know, I think it's really kind of too bad. There's really going to be no regulatory approach for this consideration. So using BRAF and MEK inhibition in stage II is not going to be part of standard practice moving into the future. To your point, though, about where will the field go? I think what we're already realizing is that in the adjuvant setting, we're really overtreating the total population. And so beyond merely staging by AJCC criteria, we need to move to biomarker selection to help inform which patients truly need the treatment. And in that regard, I don't think we've crystallized together as a field as yet, but the kinds of things that people are thinking about are the integration of molecular biomarkers like ctDNA. When it's positive, it can be very helpful, but in melanoma, we found that, unfortunately, the rates are quite low, you know, in the 10% to 15% range in the adjuvant setting. So then another consideration would be factors in the primary tumor, such as gene expression profiling or other considerations.  And so I think the future of adjuvant clinical trials will be an integration of both the standard AJCC staging system as well as some kind of overlaid molecular biomarker that helps to enrich for a higher-risk population of patients because on a high level, when you abstract out, it's just clearly the case that we're rather substantially overtreating the totality of the population, especially given that in all of our adjuvant studies to date for anti–PD-1, we have not yet shown that there's an overall survival advantage. And so some are even arguing perhaps we should even reserve treatment until patients progress. I think that's a complicated subject, and standard of care at this point is to offer adjuvant therapy, but certainly a lot more to do because many patients, you know, unfortunately, still do progress and move on to metastatic disease. Dr. Diwakar Davar: Let's transition to Abstract 2508. So we're moving on from the melanoma to the novel immunotherapy abstracts. And this is a very, very, very fascinating drug. It's IMA203. So Abstract 2508 is a phase 1 clinical update of IMA203. IMA203 is an autologous TCR-T construct targeting PRAME in patients with heavily pretreated PD-1-refractory metastatic melanoma. So Jason, in the PD-1 and CTLA-4-refractory settings, treatment options are either autologous TIL, response rate, you know, ballpark 29% to 31%, oncolytic viral therapy, RP1 with nivolumab, ORR about 30-ish percent. So new options are needed. Can you tell us a little bit about IMA203? Perhaps tell us for the audience, what is the difference between a TCR-T and traditional autologous TIL? And a little bit about this drug, IMA203, and how it distinguishes itself from the competing TIL products in the landscape. Dr. Jason Luke: I'm extremely enthusiastic about IMA203. I think that it really has transformative potential based on these results and hopefully from the phase 3 trial that's open to accrual now. So, what is IMA203? We said it's a TCR-T cell product. So what that means is that T cells are removed from a patient, and then they can be transduced through various technologies, but inserted into those T cells, we can then add a T-cell receptor that's very specific to a single antigen, and in this case, it's PRAME. So that then is contrasted quite a bit from the TIL process, which includes a surgical resection of a tumor where T cells are removed, but they're not specific necessarily to the cancer, and they're grown up in the lab and then given to the patient. They're both adoptive cell transfer products, but they're very different. One is genetically modified, and the other one is not. And so the process for generating a TCR-T cell is that patients are required to have a new biomarker that some may not be familiar with, which is HLA profiling. So the T-cell receptor requires matching to the concomitant HLA for which the peptide is bound in. And so the classic one that is used in most oncology practices is A*02:01 because approximately 48% of Caucasians have A*02:01, and the frequency of HLA in other ethnicities starts to become highly variable. But in patients who are identified to have A*02:01 genotype, we can then remove blood via leukapheresis or an apheresis product, and then insert via lentiviral transduction this T-cell receptor targeting PRAME. Patients are then brought back to the hospital where they can receive lymphodepleting chemotherapy and then receive the reinfusion of the TCR-T cells. Again, in contrast with the TIL process, however, these T cells are extremely potent, and we do not need to give high-dose interleukin-2, which is administered in the context of TIL. Given that process, we have this clinical trial in front of us now, and at ASCO, the update was from the phase 1 study, which was looking at IMA203 in an efficacy population of melanoma patients who were refractory at checkpoint blockade and actually multiple lines of therapy. So here, there were 33 patients and a response rate of approximately 50% was observed in this population of patients, notably with a duration of response approximately a year in that treatment group. And I realize that these were heavily pretreated patients who had a range of very high-risk features. And approximately half the population had uveal melanoma, which people may be aware is a generally speaking more difficult-to-treat subtype of melanoma that metastasizes to the liver, which again has been a site of resistance to cancer immunotherapy. So these results are extremely promising. To summarize them from what I said, it's easier to make TCR-T cells because we can remove blood from the patient to transduce the T cells, and we don't have to put them through surgery. We can then infuse them, and based on these results, it looks like the response rate to IMA203 is a little bit more than double what we expect from lifileucel. And then, whereas with lifileucel or TILs, we have to give high-dose IL-2, here we do not have to give high-dose IL-2. And so that's pretty promising. And a clinical trial is ongoing now called the SUPREME phase 3 clinical trial, which is hoping to validate these results in a randomized global study. Dr. Diwakar Davar: Now, one thing that I wanted to go over with you, because you know this trial particularly well, is what you think of the likelihood of success, and then we'll talk a little bit about the trial design. But in your mind, do you think that this is a trial that has got a reasonable likelihood of success, maybe even a high likelihood of success? And maybe let's contextualize that to say an alternative trial, such as, for example, the TebeAM trial, which is essentially a T-cell bispecific targeting GP100. It's being compared against SOC, investigator's choice control, also in a similarly heavily pretreated patient population. Dr. Jason Luke: So both trials, I think, have a strong chance of success. They are very different kinds of agents. And so the CD3 bispecific that you referred to, tebentafusp, likely has an effect of delaying progression, which in patients with advanced disease could have a value that might manifest as overall survival. With TCR-T cells, by contrast, we see a very high response rate with some of the patients going into very durable long-term benefit. And so I do think that the SUPREME clinical trial has a very high chance of success. It will be the first clinical trial in solid tumor oncology randomizing patients to receive a cell therapy as compared with a standard of care. And within that standard of care control arm, TILs are allowed as a treatment. And so it will also be the first study that will compare TCR-T cells against TILs in a randomized phase 3. But going back to the data that we've seen in the phase 1 trial, what we observe is that the duration of response is really connected to the quality of the response, meaning if you have more than a 50% tumor shrinkage, those patients do very, very well. But even in patients who have less than 50% tumor shrinkage, the median progression-free survival right now is about 4.5 months. And again, as we think about trial design, standard of care options for patients who are in this situation are unfortunately very bad. And the progression-free survival in that population is probably more like 2 months. So this is a trial that has a very high likelihood of being positive because the possibility of long-term response is there, but even for patients who don't get a durable response, they're likely going to benefit more than they would have based on standard chemotherapy or retreatment with an anti–PD-1 agent. Dr. Diwakar Davar: Really, a very important trial to enroll, a trial that is first in many ways. First of a new generation of TCR-T agents, first trial to look at cell therapy in the control arm, a new standard of efficacy, but potentially also if this trial is successful, it will also be a new standard of trial conduct, a new kind of trial, of a set of trials that will be done in the second-line immunotherapy-refractory space. So let's pivot to the last trial that we were going to discuss, which was Abstract 2501. Abstract 2501 is a first-in-human phase 1/2 trial evaluating BNT142, which is the first-in-class mRNA-encoded bispecific targeting Claudin-6 and CD3 in patients with Claudin-positive tumors. We'll talk a little bit about this, but maybe let's start by talking a little bit about Claudin-6. So Claudin-6 is a very interesting new target. It's a target that's highly expressed in GI and ovarian tumors. There are a whole plethora of Claudin-6-targeting agents, including T-cell bispecifics and Claudin-6-directed CAR-Ts that are being developed. But BNT142 is novel. It's a novel lipid nanoparticle LNP-encapsulated mRNA. The mRNA encodes an anti–Claudin-6 CD3 bispecific termed RiboMAB-021. And it then is administered to the patient. The BNT142-encoding mRNA LNPs are taken up by the liver and translated into the active drug. So Jason, tell us a little bit about this agent. Why you think it's novel, if you think it's novel, and let's talk a little bit then about the results. Dr. Jason Luke: So I certainly think this is a novel agent, and I think this is just the first of what will probably become a new paradigm in oncology drug development. And so you alluded to this, but just to rehash it quickly, the drug is encoded as genetic information that's placed in the lipid nanoparticle and then is infused into the patient. And after the lipid nanoparticles are taken up by the liver, which is the most common place that LNPs are usually taken up, that genetic material in the mRNA starts to be translated into the actual protein, and that protein is the drug. So this is in vivo generation, so the patient is making their own drug inside their body. I think it's a really, really interesting approach. So for any drug that could be encoded as a genetic sequence, and in this case, it's a bispecific, as you mentioned, CD3-Claudin-6 engager, this could have a tremendous impact on how we think about pharmacology and novel drug development moving into the future in oncology. So I think it's an extremely interesting drug, the like of which we'll probably see only more moving forward. Dr. Diwakar Davar: Let's maybe briefly talk about the results. You know, the patient population was heavily pretreated, 65 or so patients, mostly ovarian cancer. Two-thirds of the patients were ovarian cancer, the rest were germ cell and lung cancer patients. But let's talk a little bit about the efficacy. The disease control rate was about 58% in the phase 1 population as a whole, but 75% in the ovarian patient population. Now tell us a little bit about the interesting things about the drug in terms of the pharmacokinetics, and also then maybe we can pivot to the clinical activity by dose level. Dr. Jason Luke: Well, so they did present in their presentation at ASCO a proportionality showing that as higher doses were administered, that greater amounts of the drug were being made inside the patient. And so that's an interesting observation, and it's an important one, right? Suggesting that the pharmacology that we classically think of by administering drugs by IV, for example, would still be in play. And that did translate into some level of efficacy, particularly at the higher dose levels. Now, the caveat that I'll make a note of is that disease control rate is an endpoint that I think we have to be careful about because what that really means is sometimes a little bit unclear. Sometimes patients have slowly growing tumors and so on and so forth. And the clinical relevance of disease control, if it doesn't last at least 6 months, I think is probably pretty questionable. So I think these are extremely interesting data, and there's some preliminary sense that getting the dose up is going to matter because the treatment responses were mostly observed at the highest dose levels. There's also a caveat, however, that across the field of CD3 bispecific molecules like this, there's been quite a bit of heterogeneity in terms of the response rate, with some of them only really generating stable disease responses and other ones having more robust responses. And so I think this is a really interesting initial foray into this space. My best understanding is this molecule is not moving forward further after this, but I think that this really does set it up to be able to chase after multiple different drug targets on a CD3 bispecific backbone, both in ovarian cancer, but then basically across all of oncology. Dr. Diwakar Davar: Perfect. This is a very new sort of exciting arena where we're going to be looking at, in many ways, these programmable constructs, whether we're looking at in vivo-generated, in this case, a T-cell bispecific, but we've also got newer drugs where we are essentially giving drugs where people are generating in vivo CAR T, and also potentially even in vivo TCR-T. But certainly lots of new excitement around this entire class of drugs. And so, what we'd like to do at this point in time is switch to essentially the fact that we've got a very, very exciting set of data at ASCO 2025. You've heard from Dr. Luke regarding the advances in both early drug development but also in advanced cutaneous melanoma. And Jason, as always, thank you so much for sharing your very valuable and great, fantastic insights with us on the ASCO Daily News Podcast. Dr. Jason Luke: Well, thanks again for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for taking your time to listen today. You will find the links to the abstracts that we discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:    Dr. Diwakar Davar    @diwakardavar    Dr. Jason Luke @jasonlukemd Follow ASCO on social media:     @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn   Disclosures:     Dr. Diwakar Davar:      Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences     Consulting or Advisory Role: Instil Bio, Vedanta Biosciences     Consulting or Advisory Role (Immediate family member): Shionogi     Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences     Research Funding (Inst.): Zucero Therapeutics     Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy     Dr. Jason Luke:     Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX     Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine     Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure     Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)     Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

For anyone who's been hoping for a surprise to boost markets recently, good news came from an unexpected place earlier this month. After months and months of delay, and multiple anonymous sources suggesting that biofuel levels were set to disappoint the industry, the actual numbers announced by EPA stunned watchers with a proposed 2 billion gallon jump up in the biomass based diesel requirements. And that was just the start of the upside news on renewable fuels.To help us follow the twists and turns of the latest updates, DTN Staff reporter Todd Neeley joins us today with analysis on the EPA's proposal, as well as news from the courts, state policy, and beyond. We'll dig into the RFS ethanol levels as set in the proposal, as well as what still might be ahead this summer for E15, especially with recent positive changes coming out of California. We'll also get an update on the state of the RINs market and a legal step forward for small refinery waivers. We'll also venture beyond the fuels space to hear news about the Make America Healthy Again, or MAHA, report, and get a breakdown on how ag has and hasn't been included, and what the next steps may be. Finally, we'll hear more on some emerging lawsuits around discrimination, glyphosate liability.

Tracey Olson, COO at Guardian Energy Management and NDCGA Industry Representative, discusses the EPA's announcement of proposed RFS volume obligations for 2026 and 2027.See omnystudio.com/listener for privacy information.

Raidījumā Piespēle pirmo reizi pēc formāta maiņas runājam par ātrumlaivu sportu. Nesen par Eiropas čempionu F-2 klasē kļuva Latvijas labākais ātrumlaivu sportists Ņikita Lijcs. Viņš stāsta par šī sporta veida popularitāti Latvijā, kā arī saviem nākotnes plāniem. Nedēļas topā: Uvis Balinskis un Floridas “Panthers” otro gadu pēc kārtas triumfē Nacionālās hokeja līgas Stenlija kausa finālsērijā, šogad sešās spēlēs uzvar Edmontonas “Oilers”; Amerikas Hokeja līgas finālsērijā būs vajadzīgas vismaz sešas spēles - Artūram Šilovam un Ebotsfordas “Canucks” pagaidām nav izdevies iegūt Kaldera kausu, bet sērijā 3-2 pret Sanda Vilmaņa pārstāvēto Šārlotes “Checkers”; Kitija Laksa rezultatīvi turpina spēlēt Sieviešu Nacionālajā basketbola asociācijā, bet Fīniksas “Mercury” izvirzās līgas vadošajās pozīcijās; Latvijas futbola virslīgas otrais aplis noslēdzas ar Rīgas derbiju, tajā šoreiz pēc ilgāka pārtraukuma noskaidro uzvarētāju - kopvērtējuma līdere “Riga” ar 3:1 uzveic RFS un palielina pārsvaru skrējienā pēc čempiontitula.

In this week's episode, we explore the USDA's new solution to combat the New World Screwworm, break down the EPA's latest Renewable Fuel Standard and sit down with a soybean crusher who shares how he got his start in the biodiesel industry. In the news, President Trump halts immigration raids on farms and food plants after pushback from ag groups. An Indiana equipment dealer faces 17 felony charges in a $750,000 farm fraud case. We broke down the EPA's new Renewable Fuel Standard. Plus, China reopens trade to over 100 U.S. meat plants, fertilizer markets tighten amid global conflict and Capitol Hill cools off with the dairy industry's annual ice cream celebration. This week's interview shares some of the uncertainty leading up to the Environmental Protection Agency's recent guidance on the Renewable Fuel Standard (RFS) released this past week. Michelle Stangler visited Incobrasa, a soybean crush and biodiesel facility in Illinois, where she spoke with Quality Control Manager Kerry Fogarty during a tour organized by the Clean Fuels Alliance America. Fogarty shared insights on the history of the biodiesel tax incentive, the impact of recent plant shutdowns and what the RFS means to facilities like Incobrasa. He also discussed the uncertainty surrounding expansion projects at the facility, along with concerns about the recent cutbacks to the USAID program. The conversation highlighted both challenges and opportunities for soybean-based fuels moving forward. Stay connected with us for more agriculture content on Instagram, TikTok, Facebook, and YouTube, along with our weekly videos!

This Farm Talk segment features Tracey Olson, COO at Guardian Energy Management and North Dakota Corn Growers Association Industry Representative. Olson discusses the recent EPA announcement of proposed RFS volume obligations for 2026 and 2027. See omnystudio.com/listener for privacy information.

Steven Johnson, retired Iowa State Extension farm management specialist; Ken Ericksen, Polaris Analytics and Consulting, trends in ag trade and barge transport

There is mixed trade to begin the week with continued support for beans and soybean oil following the EPA announcements on the RFS. Greg McBride of Allendale joins Mark Magnuson for today's opening market podcast.

Von Christine Mayrhofer. Von 13. bis 15. Mai sind Österreichs Studierende zur Wahl aufgerufen. Was versprechen und fordern die elf antretenden Listen und Fraktionen? Und wieso ist die Wahlbeteiligung bei ÖH-Wahlen traditionell so niedrig?

A bi-partisan letter from U.S. Senators was sent to EPA urging the agency to raise RFS volumes. Paul Winters, director, public affairs and federal communications for Clean Fuels Alliance America, joins us to discuss the details. This week's Farmer Forum features Tim Burrack of Iowa and Sherman Newlin of Illinois.See omnystudio.com/listener for privacy information.

On this episode of Agriculture Today, we'll learn about some reports that the USDA will once again be distributing, takeaways from the most recent USDA supply and demand report, continued debate over the RFS, and some comments from the U.S. EPA administrator on the review of crop protection tools.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Rīgā pārspējot Amsterdamas "Ajax", RFS kļuva par pirmo Latvijas futbola klubu, kas izcīnījis uzvaru Eirokausu pamatturnīrā. Astoņās spēlēs iegūti pieci punkti, ierindojoties 32. vietā. Lai noskaidrotu, kurš futbolists visvairāk pacēla savu vērtību, ko starts UEFA Eiropas līgā nesa Latvijai un kas tika izdarīts nepareizi, sagaidot "Ajax" ultras, Ulvis Brože studijā aicināja Sportacentrs.com futbola cilvēku Agri Suveizdu un "Go3" futbola komentētāju Arkādiju Birjuku. Sportacentrs.com podkāsts Ārpus kadra – katru trešdienas vakaru kanālā TV4, portālā Sportacentrs.com un visās populārākajās audio straumēšanas platformās. Ārpus kadra 2025. gadā uz priekšu dzen oficiālais KTM un MERIDA velosipēdu pārstāvis Latvijā AstraVelo, bet podkāstam veldzi nodrošina Vytautas minerālūdens

On Tuesday's AOA, we kick off the show with an update on 45Z, RFS and more with Kurk Kovarik from Clean Fuels Alliance America. Then we continue our coverage of the AgMarket.net “Farming for Profit, Not Price” conference and have a conversation with Dan Basse from AgResource Company. Then, we sit down with Matt Bennett from AgMarket.net in Segment Three and close the show with a cattle market outlook from Ross Baldwin of AgMarket.net.  

De griepgolf heeft ook de Pantelic Podcast bereikt, maar Bart en Jan zorgen online toch gewoon voor een nieuwe Pantelic Podcast. En dat is maar goed ook, want het is de week van de waarheid voor Ajax. Met Galatasaray, maar vooral De Klassieker aankomende zondag staat er nogal wat op het programma. Ze bespreken de wedstrijden voor, maar ook zeker de andere manier waarop het de week van de waarheid is. Namelijk die voor Alex Kroes. Het is nog still op de transfermarkt. En Kroes is na vijf maanden terug bij af, want Carlos Forbs lijkt de nieuwe (oude) linksbuiten te gaan worden. Hij moet nu echt aan de bak met de naderende transfer deadline!(00:00) Intro(01:20) Nog even RFS(10:10) Druk op Kroes neemt toe(25:55) Uitgaand gebeurt er wel wat(31:28) Interesse in Cedric Hatenboer(34:08) Speculaties rond Brobbey(39:46) Galatasaray zonder Ziyech in de Arena(43:18) De Klassieker(52:32) Het Pantelic Plakboek(56:32) Jong Ajax stelt teleurZie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

Our first Europa League match-day of the year! The week kicked off in dramatic fashion around Istanbul - Kyiv stunning Galatasaray on Tuesday with a comeback draw for their first point of the campaign, then Besiktas taking it to Athletic Club on Wednesday in Ole Gunnar Solskjær's first game in charge. Thursday featured a slate of big clubs going head-to-head, where Sociedad, Roma, Fenerbahce failed to show up, pushing them dangerously close to missing out on qualification. Elsewhere, Tottenham and Hoffenheim remain maddeningly inconsistent, and RFS pulls off their first ever Europa League win against the mighty Ajax. We also turn to January 30's games - the final match-day of the inaugural League Phase - and discuss all the important fixtures and table scenarios. Cheers Dino Toppmöller!

15min tinklalaidėje apie Lietuvos ir pasaulio futbolą „Skrieja kamuolys“ – žaidimų konsolės, geriausiųjų rinkimai, Vilniaus „Riterių“ investuotojai, „draugiškos“ Matijaus Remeikio rungtynės su Rusijos klubu, brangiausia futbolininkė istorijoje, „Bayern“ paslydimas Roterdame, „El Cashico“, Čempionų lygos formatas, nauja geriausia komanda pasaulyje, A.Chusanovo kliurkos ir kitoks „Manchester City“ žaidimas, vargo vakarienė „Tottenham“ bei „Manchester United“ stovyklose, Mariaus kelionė į Rygą, kur RFS paguldė „Ajax“, ispanų, vokiečių ir italų lygos. Prie mikrofonų – 15min sporto žurnalistai Aurimas Tamulionis ir Marius Bagdonas bei „Go3“ komentatoriai Rytis Vyšniauskas ir Karolis Dudėnas. 00:00 Konsolės ir Mariaus prisiminimas iš vaikystės 07:44 Geriausi Lietuvos metų futbolininkai 12:08 Kas tie Vilniaus „Riterių“ investuotojai? 18:24 Lietuvos klubų kontroliniai mūšiai 32:13 Gineitis turės dar vieną konkurentą? 33:31 Kiti lietuviai svetur ir Remeikio mačas su rusais 37:07 Salės futbolas ir brangiausia futbolininkė istorijoje 40:10 „Bayern“ sumuštas Roterdame, „Man City“ – Paryžiuje 51:09 Kaip jums naujasis Čempionų lygos formatas? 1:06:10 Istorinė savaitė Lietuvos teisėjams 1:08:37 Geriausia komanda pasaulyje ir „Liverpool“ 1:20:59 Chusavono kliurkos, Pepas ir kitoks „Man City“ 1:32:43 „Tottenham“ ir „Man United“ vargas 1:39:51 RFS paguldė „Ajax“ – Mariaus įspūdžiai iš Rygos 1:45:42 K.Mbappe hat-trickas ir G.Neville‘o šmėkla 1:53:50 Į gynybą atsitraukęs „Bayer“ ir pramušęs H.Kane‘as 2:02:44 „Napoli“ aukštaūgiai ir cirkai Milane

Rechtstreeks uit het vliegtuig vanuit Letland probeert Arco met Freek de kater van de 1-0 nederlaag van Ajax bij RFS weg te spoelen in een nieuwe aflevering van de Pak Schaal Podcast. Hoe was het in Riga? Ook de concrete interesse in Brian Brobbey van West Ham United pakken we mee.Zie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

Un poco de competiciones mainstream: qué va a pasar en la última jornada de la Champions y quién va a ser el portero del Barça en los próximos partidos. Y el underground habitual: cosas de copas portuguesas, del histórico triunfo del RFS letón, de la gran aparición del momento en la segunda española... También: Rueda de Prensa y Comunicado por el Borrado del Podcast Efímero.

Feyenoord kwam een dag na de zege op Bayern München met duidelijkheid over de positie van de trainer. Brian Priske mag blijven bij de club uit Rotterdam. En dat na dagen van speculaties over zijn positie. In de Europa League wonnen AZ en FC Twente hun wedstrijd. Ajax verloor in Riga met 1-0 van RFS na een hele slechte wedstrijd. In de AD Voetbalpodcast bespreekt Etienne Verhoeff met Sjoerd Mossou deze zaken en Lex Lammers kijkt naar de KKD. ,,Die quotes van Dennis te Kloese zeggen niet zo veel en is gezwets in de ruimte", vertelt Mossou over het aanblijven van Priske. ,,Na grote twijfels en een crisisberaad waarbij ze dachten aan een ontslag, mag hij toch blijven. Als je de optelsom met de voors en tegens naast elkaar, vind ik het wel een logische conclusie dat Priske mag blijven. Bovendien: wat is het alternatief? Wie is er beschikbaar als vervanger?"Ook bespreken ze Europese avond in de Europa League. ,,Het was bijna een perfecte week voor de Nederlandse club in Europa en de coëfficiëntenlijst. Alleen Ajax liet het afweten in Riga. Dat was wel een afgang in de Europese geschiedenis van de club." Beluister de hele AD Voetbalpodcast nu via AD.nl, de AD App of jouw favoriete podcastplatform. Vergeet je niet te abonneren op de podcast. Dan krijg je elke dag de nieuwe show automatisch in je playlist.Support the show: https://krant.nlSee omnystudio.com/listener for privacy information.

Een wanvertoning van Ajax in Letland. Er werd met 1-0 van RFS verloren. Bart Obbink en Jan Verdonk spreken het na in de Wedstrijdeditie.Wedstrijdwoord niet gewonnen en toch 'Eenmalige Ajacieden' willen lezen?Bestel hem dan op: https://boekengilde.nl/boekenshop/eenmalige-ajacieden/?srsltid=AfmBOoprtZVdSRy5vaNGwUSgp1Oh3shzb7iNxw_uQ0c8rgY3lpGaH9mUZie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

The roller coaster of news concerning the continuing resolution means getting the perspectives of a variety of folks concerned with U.S. agriculture. We discuss the ag economy and rural banking with Alan Hoskins, president of American Farm Mortgage & Financial Services. Robert White, senior vice president of industry relations and market development at the Renewable Fuels Association, talks about E15 and the RFS. Paul Neiffer, a.k.a. The Farm CPA, also chimes in about the status of the CR and farm aid.See omnystudio.com/listener for privacy information.

מכבי תל אביב ניצחה אמש (חמישי) 1:2 את RFS הלטבית בליגה האירופית והכניסה את עצמה לתמונת העלייה לפלייאוף של המפעל כשהיא עם שש נקודות. הצהובים שרדו דרמה מוכרת, כזו שהתרחשה רק לפני שבוע בדיוק, כאשר בדקה ה-100 הפועל חדרה השוותה אחרי פנדל שרועי משפתי הצליח להדוף. הפעם, משפתי שבעצמו גרם לפנדל, הצליח גם לקלוט את הכדור באופן סופי ולהבטיח ניצחון לצהובים, שמצד אחד יכולים לשמוח ולחגוג, אבל מצד שני חייבים להבין איך האירועים האלה קורים להם שוב (פנדל שלישי העונה אחרי הדקה ה-90). וגם: הבישולים של פטאצ׳י, השערים הקשים של נחמיאס וסטואיץ׳, הדקות האחרונות וההתנהלות של תורג׳מן, דוידה ויחזקאל, הראיון של לאזטיץ׳ ובחירת השחקנים שלו בתוך המערך שבו הוא מאמין. רז אמיר ואורן קדוש מסכמים ניצחון באירופה תמונת קאבר: רויטרסSee omnystudio.com/listener for privacy information.

In the wake of the elections in the US, RINS Reporter Matthew Cope and US Products Associate Editor Jason Metko play a game of "hit the brakes or hit the gas" to discuss some of the potential effects on the biofuels industry - particularly important to the Renewable Fuel Standard (RFS) and road fuels - under a second Donald Trump administration.  Listen to find out if it's "hit the brakes" or "hit the gas" as we address issues including: Should we expect Small Refinery Exemptions (SREs) to return under the new Trump administration? Trump's pick to lead the Environmental Protection Agency (EPA), Lee Zeldin, previously backed a bill to eliminate the RFS. Would he do that now? Trump has expressed the desire to get rid of electric vehicle (EV) subsidies. However, with Elon Musk operating an EV company, will he push Trump for more incentives? Biden took a less favourable approach towards E15. Will it be different with Trump's return?

Một cuộc tàn sát chết người ở miền trung Sudan do lực lượng bán quân sự RFS thực hiện đã khiến ít nhất 124 người thiệt mạng và hàng chục người dân địa phương bị thương và phải di tản. SBS News đã nói chuyện với một phụ nữ Úc gốc Sudan ở Sydney, người có các thành viên trong gia đình đã thiệt mạng, bị thương và phải di tản trong các cuộc tấn công, trong khi người anh trai 27 tuổi Ibrahim của cô vẫn mất tích.

Michelle has over 20 years of experience in Financial Services and her main goal is to always focus on her client's long-term financial planning strategy to optimize retirement income.She prides herself on analyzing a financial situation, finding any potential issues, and creating adequate solutions to ensure her clients' prosperous future. With her extensive insurance and planning experience, Michelle adds great knowledge to the already specialized team at RFS.She has worked in various capacities in the financial industry from being part of top producer teams to teaching new financial advisors through agency leadership. Michelle's passion is to help educate consumers by taking complex financial strategies and explaining them in an easy way to understand the concept. Michelle is originally from Pittsburgh, PA, and a graduate of Penn State University in Business.She now resides in Boynton Beach, FL with her husband Rob, their two daughters Olivia and London, and their three pets. When Michelle isn't working with RFS's clients or spending time with her family, she is likely exercising or on her Peloton, competing her way to the top of the leaderboard. Michelle has always loved sports as she grew up playing Basketball, Volleyball, and Softball. While living in Pittsburgh, she became part of Steeler Nation, and that devotion has carried with her to South Florida.Michelle joined Rosenzweig Financial Services in October 2021 as Vice President, specializing in the professional marketplace.Learn more: https://www.rfsny.com/Registered representative of, and securities and investment advisory services offered through Hornor, Townsend & Kent, LLC (HTK), Registered Investment Adviser, Member FINRA/SIPC, 1 North Federal Hwy, Suite 201, Boca Raton, FL 33432. 561-314-3100, http://www.htk.com. HTK is a wholly-owned subsidiary of The Penn Mutual Life Insurance Company. Rosenzweig Financial Services is unaffiliated with HTK. HTK does not offer tax or legal advice. Always consult a qualified adviser regarding your individual circumstances.Retirement Income Authority is not affiliated with HTKInfluential Entrepreneurs with Mike Saundershttps://businessinnovatorsradio.com/influential-entrepreneurs-with-mike-saunders/Source: https://businessinnovatorsradio.com/interview-w-michelle-boyce-ricp-vp-w-rosenzweig-financial-services-discussing-the-power-of-tax-free-income

Michelle has over 20 years of experience in Financial Services and her main goal is to always focus on her client's long-term financial planning strategy to optimize retirement income.She prides herself on analyzing a financial situation, finding any potential issues, and creating adequate solutions to ensure her clients' prosperous future. With her extensive insurance and planning experience, Michelle adds great knowledge to the already specialized team at RFS.She has worked in various capacities in the financial industry from being part of top producer teams to teaching new financial advisors through agency leadership. Michelle's passion is to help educate consumers by taking complex financial strategies and explaining them in an easy way to understand the concept. Michelle is originally from Pittsburgh, PA, and a graduate of Penn State University in Business.She now resides in Boynton Beach, FL with her husband Rob, their two daughters Olivia and London, and their three pets. When Michelle isn't working with RFS's clients or spending time with her family, she is likely exercising or on her Peloton, competing her way to the top of the leaderboard. Michelle has always loved sports as she grew up playing Basketball, Volleyball, and Softball. While living in Pittsburgh, she became part of Steeler Nation, and that devotion has carried with her to South Florida.Michelle joined Rosenzweig Financial Services in October 2021 as Vice President, specializing in the professional marketplace.Learn more: https://www.rfsny.com/Registered representative of, and securities and investment advisory services offered through Hornor, Townsend & Kent, LLC (HTK), Registered Investment Adviser, Member FINRA/SIPC, 1 North Federal Hwy, Suite 201, Boca Raton, FL 33432. 561-314-3100, http://www.htk.com. HTK is a wholly-owned subsidiary of The Penn Mutual Life Insurance Company. Rosenzweig Financial Services is unaffiliated with HTK. HTK does not offer tax or legal advice. Always consult a qualified adviser regarding your individual circumstances.Retirement Income Authority is not affiliated with HTKInfluential Entrepreneurs with Mike Saundershttps://businessinnovatorsradio.com/influential-entrepreneurs-with-mike-saunders/Source: https://businessinnovatorsradio.com/interview-w-michelle-boyce-ricp-vp-w-rosenzweig-financial-services-discussing-the-power-of-tax-free-income

Michelle has over 20 years of experience in Financial Services and her main goal is to always focus on her client's long-term financial planning strategy to optimize retirement income.She prides herself on analyzing a financial situation, finding any potential issues, and creating adequate solutions to ensure her clients' prosperous future. With her extensive insurance and planning experience, Michelle adds great knowledge to the already specialized team at RFS.She has worked in various capacities in the financial industry from being part of top producer teams to teaching new financial advisors through agency leadership. Michelle's passion is to help educate consumers by taking complex financial strategies and explaining them in an easy way to understand the concept. Michelle is originally from Pittsburgh, PA and a graduate from Penn State University in Business.She now resides in Boynton Beach, FL with her husband Rob, their two daughters Olivia andLondon, and their three pets. When Michelle isn't working with RFS's clients or spending time with her family, she is likely exercising or on her Peloton, competing her way to the top of the leaderboard. Michelle has always loved sports as she grew up playing Basketball, Volleyball, and Softball. While living in Pittsburgh, she became part of Steeler Nation and that devotion has carried with her to South Florida.Michelle joined Rosenzweig Financial Services in October 2021 as Vice President, specializing in the professional marketplace.Learn more: https://www.rfsny.com/Registered representative of, and securities and investment advisory services offered through Hornor, Townsend & Kent, LLC (HTK), Registered Investment Adviser, Member FINRA/SIPC, 1 North Federal Hwy, Suite 201, Boca Raton, FL 33432. 561-314-3100, http://www.htk.com. HTK is a wholly-owned subsidiary of The Penn Mutual Life Insurance Company. Rosenzweig Financial Services is unaffiliated with HTK. HTK does not offer tax or legal advice. Always consult a qualified adviser regarding your individual circumstances.Retirement Income Authority is not affiliated with HTKInfluential Entrepreneurs with Mike Saundershttps://businessinnovatorsradio.com/influential-entrepreneurs-with-mike-saunders/Source: https://businessinnovatorsradio.com/interview-w-michelle-boyce-ricp-vp-w-rosenzweig-financial-services-discussing-guaranteed-income-streams

Michelle has over 20 years of experience in Financial Services and her main goal is to always focus on her client's long-term financial planning strategy to optimize retirement income.She prides herself on analyzing a financial situation, finding any potential issues, and creating adequate solutions to ensure her clients' prosperous future. With her extensive insurance and planning experience, Michelle adds great knowledge to the already specialized team at RFS.She has worked in various capacities in the financial industry from being part of top producer teams to teaching new financial advisors through agency leadership. Michelle's passion is to help educate consumers by taking complex financial strategies and explaining them in an easy way to understand the concept. Michelle is originally from Pittsburgh, PA, and a graduate from Penn State University in Business.She now resides in Boynton Beach, FL with her husband Rob, their two daughters Olivia and London, and their three pets. When Michelle isn't working with RFS's clients or spending time with her family, she is likely exercising or on her Peloton, competing her way to the top of the leaderboard.Michelle has always loved sports as she grew up playing Basketball, Volleyball, and Softball. While living in Pittsburgh, she became part of Steeler Nation and that devotion has carried with her to South Florida.Michelle joined Rosenzweig Financial Services in October 2021 as Vice President, specializing in the professional marketplace.Learn more: https://www.rfsny.com/Registered representative of, and securities and investment advisory services offered through Hornor, Townsend & Kent, LLC (HTK), Registered Investment Adviser, Member FINRA/SIPC, 1 North Federal Hwy, Suite 201, Boca Raton, FL 33432. 561-314-3100, http://www.htk.com. HTK is a wholly-owned subsidiary of The Penn Mutual Life Insurance Company. Rosenzweig Financial Services is unaffiliated with HTK. HTK does not offer tax or legal advice. Always consult a qualified adviser regarding your individual circumstances.Retirement Income Authority is not affiliated with HTKInfluential Entrepreneurs with Mike Saundershttps://businessinnovatorsradio.com/influential-entrepreneurs-with-mike-saunders/Source: https://businessinnovatorsradio.com/interview-w-michelle-boyce-ricp-vp-w-rosenzweig-financial-services-discussing-qualified-funds-how-is-too-much

Michelle has over 20 years of experience in Financial Services and her main goal is to always focus on her client's long-term financial planning strategy to optimize retirement income.She prides herself on analyzing a financial situation, finding any potential issues, and creating adequate solutions to ensure her clients' prosperous future. With her extensive insurance and planning experience, Michelle adds great knowledge to the already specialized team at RFS.She has worked in various capacities in the financial industry from being part of top producer teams to teaching new financial advisors through agency leadership. Michelle's passion is to help educate consumers by taking complex financial strategies and explaining them in an easy way to understand the concept. Michelle is originally from Pittsburgh, PA, and a graduate from Penn State University in Business.She now resides in Boynton Beach, FL with her husband Rob, their two daughters Olivia and London, and their three pets. When Michelle isn't working with RFS's clients or spending time with her family, she is likely exercising or on her Peloton, competing her way to the top of the leaderboard.Michelle has always loved sports as she grew up playing Basketball, Volleyball, and Softball. While living in Pittsburgh, she became part of Steeler Nation and that devotion has carried with her to South Florida.Michelle joined Rosenzweig Financial Services in October 2021 as Vice President, specializing in the professional marketplace.Learn more: https://www.rfsny.com/Registered representative of, and securities and investment advisory services offered through Hornor, Townsend & Kent, LLC (HTK), Registered Investment Adviser, Member FINRA/SIPC, 1 North Federal Hwy, Suite 201, Boca Raton, FL 33432. 561-314-3100, http://www.htk.com. HTK is a wholly-owned subsidiary of The Penn Mutual Life Insurance Company. Rosenzweig Financial Services is unaffiliated with HTK. HTK does not offer tax or legal advice. Always consult a qualified adviser regarding your individual circumstances.Retirement Income Authority is not affiliated with HTKInfluential Entrepreneurs with Mike Saundershttps://businessinnovatorsradio.com/influential-entrepreneurs-with-mike-saunders/Source: https://businessinnovatorsradio.com/interview-w-michelle-boyce-ricp-vp-w-rosenzweig-financial-services-discussing-qualified-funds-how-is-too-much

Michelle has over 20 years of experience in Financial Services and her main goal is to always focus on her client's long-term financial planning strategy to optimize retirement income.She prides herself on analyzing a financial situation, finding any potential issues, and creating adequate solutions to ensure her clients' prosperous future. With her extensive insurance and planning experience, Michelle adds great knowledge to the already specialized team at RFS.She has worked in various capacities in the financial industry from being part of top producer teams to teaching new financial advisors through agency leadership. Michelle's passion is to help educate consumers by taking complex financial strategies and explaining them in an easy way to understand the concept. Michelle is originally from Pittsburgh, PA and a graduate from Penn State University in Business.She now resides in Boynton Beach, FL with her husband Rob, their two daughters Olivia andLondon, and their three pets. When Michelle isn't working with RFS's clients or spending time with her family, she is likely exercising or on her Peloton, competing her way to the top of the leaderboard. Michelle has always loved sports as she grew up playing Basketball, Volleyball, and Softball. While living in Pittsburgh, she became part of Steeler Nation and that devotion has carried with her to South Florida.Michelle joined Rosenzweig Financial Services in October 2021 as Vice President, specializing in the professional marketplace.Learn more: https://www.rfsny.com/Registered representative of, and securities and investment advisory services offered through Hornor, Townsend & Kent, LLC (HTK), Registered Investment Adviser, Member FINRA/SIPC, 1 North Federal Hwy, Suite 201, Boca Raton, FL 33432. 561-314-3100, http://www.htk.com. HTK is a wholly-owned subsidiary of The Penn Mutual Life Insurance Company. Rosenzweig Financial Services is unaffiliated with HTK. HTK does not offer tax or legal advice. Always consult a qualified adviser regarding your individual circumstances.Retirement Income Authority is not affiliated with HTKInfluential Entrepreneurs with Mike Saundershttps://businessinnovatorsradio.com/influential-entrepreneurs-with-mike-saunders/Source: https://businessinnovatorsradio.com/interview-w-michelle-boyce-ricp-vp-w-rosenzweig-financial-services-discussing-guaranteed-income-streams

A Gallifrey One guest announcement tops the RFS headlines as Jenna Coleman aka Clara Oswald is set to arrive in Los Angeles this upcoming February! Plus Russell T Davies is in the latest SFX to explain how TV works to you nerds, so what better time for the Three Who Rule to add their uninformed insights to the pile? An Emperor Davros dolly is on the way from B&M, Ncuti Gatwa's theatrical spectacular The Importance of Being Earnest heads for cinema screens and more, before a Classic Series Commentary on the penultimate episode of both “Planet of the Spiders” and the Jon Pertwee era!  Links: Support Radio Free Skaro on Patreon Jenna Coleman announced as guest of Gallifrey One RTD says Season 3 renewal won't come until after Season 2 airs BFI redux screening of The Happiness Patrol on September 29 B&M 2024 Remembrance of the Daleks – Emperor Davros B&M 2024 The History of the Daleks #18 Ncuti Gatwa's The Importance of Being Earnest getting UK cinema release Doctor Who finalists for five BAFTA Cymru Awards (aka The Welshies) Breakdown of the first scene of The Power of the Daleks Commentary: Planet of the Spiders Episode 5